Please login to the form below

Intercept

This page shows the latest Intercept news and features for those working in and with pharma, biotech and healthcare.

Gilead NASH drug clears mid-stage trial, but rivals are looming

Gilead NASH drug clears mid-stage trial, but rivals are looming. Positive results to challenge Intercept in emerging disease area. ... The new data shows Gilead’s drug is working as expected, but analysts said the results don’t look particularly

Latest news

Novartis and Pfizer to collaborate on NASH combinations

needs.”. Other companies such as Intercept, Allergan and Gilead have FXR agonists in their pipelines, but Gilead suffered a disappointment when its candidate failed to show efficacy a recent phase 2 ... Intercept’s Ocaliva (obeticholic acid, an FXR
Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold), Biogen (Spinraza), Biomarin (Brineura), Eusa (Qarziba), Intercept (Ocaliva), Kyowa Kirin (Crysvita) and Shire (Revestive).
Intercept hit hard as FDA issues Ocaliva safety notice

Intercept claimed an accelerated FDA approval for Ocaliva in May 2016 and followed that with an EMA green light in December. ... Intercept can muster approvals in additional indications such as non-alcoholic steatohepatitis (NASH) for which it is in
BMS claims a win in mid-stage NASH trial

elafibranor and Intercept's Ocaliva (obeticholic acid), which is already on the market for another indication (primary biliary cholangitis).
Intercept gets EU nod for rare liver disease therapy

Intercept gets EU nod for rare liver disease therapy. Ocaliva approved as a combination treatment for primary biliary cholangitis. ... Intercept Pharma now has approval for its Ocaliva drug for primary biliary cholangitis (PBC) therapy Ocaliva on both

More from news
Approximately 6 fully matching, plus 6 partially matching documents found.

Latest Intelligence

Deal Watch June 2016

In Europe Cerus expects to apply for a CE Mark for the Intercept RBC System in the second half of 2016. ... collaboration, licence. 200. Cerus/ BARDA. Intercept, pathogen reduction technology for blood transfusions including Zika virus.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Simon Doyle joins STEM

Doyle - who joins the group from Intercept Pharmaceuticals where he was executive director of commercial operations and marketing - will be at the forefront of a number of key accounts to help
Glenn Sblendorio to retire as president of The Medicines Company

He currently serves as a director at Amicus Therapeutics, Intercept Pharmaceuticals and Ophthotech Corporation.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Blog: 5 ingredients: Multichannel marketing, simplified

Develop your communication for each channel specifically. Intercept testing: show the ad to your mother, your child, a co-worker down the hall.
Market Insights Can Deliver a Better Patient Experience

Our survey, carried out using a mobile research intercept method, found that, unfortunately, memory aids can give patients the false reassurance that they are more compliant than they actually are.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Client Services Director – Medical Education Agency – North West...: Salary TBC

Associate Director, Market Access & HEOR – North-West: Negotiable

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Scientific Director / Editorial Team Leader: Great salary and benefits

Senior Medical Writer: Competitive Salary

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Events Manager – Med Comms – Surrey: Salary TBC

Healthcare Communications Account Directors x 2: Salary TBC

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Medical Writers: Competitive Salary and Benefits

Associate Medical Director: Highly Competitive

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Associate Medical Director: Excellent PTO, bonus and 401k package

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Consultant Health Economics - London / Oxford: Negotiable

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Account Director: Excellent benefits

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Account Manager- Healthcare Advertising: Negotiable

Medical/ Scientific Director: Salary TBC

Associate Director: £75, 000-90, 000

Subscribe to our email news alerts

PMHub

Add my company

Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...